NR4A1 and breast cancer: CDK7 inhibitor can strongly diminish the transcription of a cluster of particular genes, which are overexpressed in TNBC but not in hormone receptor (HR)+ breast cancer cells containing putative oncogenes, promoting TNBC tumorigenicity and the disease development3.